Cargando…

Antioxidant Roles of SGLT2 Inhibitors in the Kidney

The reduction-oxidation (redox) system consists of the coupling and coordination of various electron gradients that are generated thanks to serial reduction-oxidation enzymatic reactions. These reactions happen in every cell and produce radical oxidants that can be mainly classified into reactive ox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Llorens-Cebrià, Carmen, Molina-Van den Bosch, Mireia, Vergara, Ander, Jacobs-Cachá, Conxita, Soler, Maria José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773577/ https://www.ncbi.nlm.nih.gov/pubmed/35053290 http://dx.doi.org/10.3390/biom12010143

Ejemplares similares

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
por: Vergara, Ander, et al.
Publicado: (2022)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model
por: Vergara, Ander, et al.
Publicado: (2021)

Revisiting Experimental Models of Diabetic Nephropathy
por: Giralt-López, Anna, et al.
Publicado: (2020)

Matrix Metalloproteinases in Diabetic Kidney Disease
por: Garcia-Fernandez, Nuria, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
por: García-Carro, Clara, et al.
Publicado: (2019)

The COVID-19 pandemic: progress in nephrology
por: Soler, María José, et al.
Publicado: (2021)

A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2021)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
por: Tsai, Kai-Fan, et al.
Publicado: (2021)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19
por: Vergara, Ander, et al.
Publicado: (2021)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

The Role of SGLT2 Inhibitors in Vascular Aging
por: Liu, Le, et al.
Publicado: (2021)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
por: Pham, Phuong-Thu T., et al.
Publicado: (2022)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
por: Pereira, Maria J., et al.
Publicado: (2019)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
por: De La Flor, José C., et al.
Publicado: (2023)

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
por: Vasquez-Rios, George, et al.
Publicado: (2020)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
por: Scisciola, Lucia, et al.
Publicado: (2023)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
por: Skrabic, Roko, et al.
Publicado: (2022)

Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors
por: Tuttle, Katherine R.
Publicado: (2023)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020)

SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
por: García-Carro, Clara, et al.
Publicado: (2021)

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
por: Nadkarni, Girish N., et al.
Publicado: (2017)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j9c961i6ve26jeu4brc05u2g5s